Are outcomes of allografts for CLL still relevant?

Abstract

In this issue of Blood, Krämer et al have provided a long-term update on the outcomes of patients enrolled in the German CLL Study Group CLL3X trial who underwent a matched related or unrelated allogeneic hematopoietic cell transplantation (allo-HCT) with a reduced-intensity fludarabine/alkylator-based approach for high-risk chronic lymphocytic leukemia (HR-CLL).1